Evidence map›Paper›PMID 26962066›Full record

ArticleNeurology2016

Sex differences in comorbidity at diagnosis of multiple sclerosis: A population-based study.

Ruth Ann Marrie, Scott B Patten, Helen Tremlett, Christina Wolfson, Sharon Warren, Lawrence W Svenson, Nathalie Jette, John Fisk, CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Comorbidity and modifiable risk factors in multiple sclerosis.Therapeutic advances in neurological disorders · 2026
    Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ruth Ann MarrieFrom the Departments of Internal Medicine (R.A.M.) and Community Health Sciences (R.A.M.), University of Manitoba; Department of Community Health Sciences (S.B.P., L.W.S., N.J.), Institute for Public Health (N.J.), Department of Clinical Neurosciences (N.J.), and Hotchkiss Brain Institute (N.J.), University of Calgary; Department of Medicine (Neurology) (H.T.), University of British Columbia, Vancouver; Department of Epidemiology and Biostatistics and Occupational Health (C.W.), McGill University, Montreal; Faculty of Rehabilitation Medicine (S.W.) and School of Public Health (L.W.S.), University of Alberta, Edmonton; Surveillance and Assessment (L.W.S.), Alberta Health, Edmonton; and Departments of Psychiatry and Medicine (J.F.), Dalhousie University, Halifax, Canada. rmarrie@hsc.mb.ca.
Scott B PattenFrom the Departments of Internal Medicine (R.A.M.) and Community Health Sciences (R.A.M.), University of Manitoba; Department of Community Health Sciences (S.B.P., L.W.S., N.J.), Institute for Public Health (N.J.), Department of Clinical Neurosciences (N.J.), and Hotchkiss Brain Institute (N.J.), University of Calgary; Department of Medicine (Neurology) (H.T.), University of British Columbia, Vancouver; Department of Epidemiology and Biostatistics and Occupational Health (C.W.), McGill University, Montreal; Faculty of Rehabilitation Medicine (S.W.) and School of Public Health (L.W.S.), University of Alberta, Edmonton; Surveillance and Assessment (L.W.S.), Alberta Health, Edmonton; and Departments of Psychiatry and Medicine (J.F.), Dalhousie University, Halifax, Canada.
Helen TremlettFrom the Departments of Internal Medicine (R.A.M.) and Community Health Sciences (R.A.M.), University of Manitoba; Department of Community Health Sciences (S.B.P., L.W.S., N.J.), Institute for Public Health (N.J.), Department of Clinical Neurosciences (N.J.), and Hotchkiss Brain Institute (N.J.), University of Calgary; Department of Medicine (Neurology) (H.T.), University of British Columbia, Vancouver; Department of Epidemiology and Biostatistics and Occupational Health (C.W.), McGill University, Montreal; Faculty of Rehabilitation Medicine (S.W.) and School of Public Health (L.W.S.), University of Alberta, Edmonton; Surveillance and Assessment (L.W.S.), Alberta Health, Edmonton; and Departments of Psychiatry and Medicine (J.F.), Dalhousie University, Halifax, Canada.
Christina WolfsonFrom the Departments of Internal Medicine (R.A.M.) and Community Health Sciences (R.A.M.), University of Manitoba; Department of Community Health Sciences (S.B.P., L.W.S., N.J.), Institute for Public Health (N.J.), Department of Clinical Neurosciences (N.J.), and Hotchkiss Brain Institute (N.J.), University of Calgary; Department of Medicine (Neurology) (H.T.), University of British Columbia, Vancouver; Department of Epidemiology and Biostatistics and Occupational Health (C.W.), McGill University, Montreal; Faculty of Rehabilitation Medicine (S.W.) and School of Public Health (L.W.S.), University of Alberta, Edmonton; Surveillance and Assessment (L.W.S.), Alberta Health, Edmonton; and Departments of Psychiatry and Medicine (J.F.), Dalhousie University, Halifax, Canada.
Sharon WarrenFrom the Departments of Internal Medicine (R.A.M.) and Community Health Sciences (R.A.M.), University of Manitoba; Department of Community Health Sciences (S.B.P., L.W.S., N.J.), Institute for Public Health (N.J.), Department of Clinical Neurosciences (N.J.), and Hotchkiss Brain Institute (N.J.), University of Calgary; Department of Medicine (Neurology) (H.T.), University of British Columbia, Vancouver; Department of Epidemiology and Biostatistics and Occupational Health (C.W.), McGill University, Montreal; Faculty of Rehabilitation Medicine (S.W.) and School of Public Health (L.W.S.), University of Alberta, Edmonton; Surveillance and Assessment (L.W.S.), Alberta Health, Edmonton; and Departments of Psychiatry and Medicine (J.F.), Dalhousie University, Halifax, Canada.
Lawrence W SvensonFrom the Departments of Internal Medicine (R.A.M.) and Community Health Sciences (R.A.M.), University of Manitoba; Department of Community Health Sciences (S.B.P., L.W.S., N.J.), Institute for Public Health (N.J.), Department of Clinical Neurosciences (N.J.), and Hotchkiss Brain Institute (N.J.), University of Calgary; Department of Medicine (Neurology) (H.T.), University of British Columbia, Vancouver; Department of Epidemiology and Biostatistics and Occupational Health (C.W.), McGill University, Montreal; Faculty of Rehabilitation Medicine (S.W.) and School of Public Health (L.W.S.), University of Alberta, Edmonton; Surveillance and Assessment (L.W.S.), Alberta Health, Edmonton; and Departments of Psychiatry and Medicine (J.F.), Dalhousie University, Halifax, Canada.
Nathalie JetteFrom the Departments of Internal Medicine (R.A.M.) and Community Health Sciences (R.A.M.), University of Manitoba; Department of Community Health Sciences (S.B.P., L.W.S., N.J.), Institute for Public Health (N.J.), Department of Clinical Neurosciences (N.J.), and Hotchkiss Brain Institute (N.J.), University of Calgary; Department of Medicine (Neurology) (H.T.), University of British Columbia, Vancouver; Department of Epidemiology and Biostatistics and Occupational Health (C.W.), McGill University, Montreal; Faculty of Rehabilitation Medicine (S.W.) and School of Public Health (L.W.S.), University of Alberta, Edmonton; Surveillance and Assessment (L.W.S.), Alberta Health, Edmonton; and Departments of Psychiatry and Medicine (J.F.), Dalhousie University, Halifax, Canada.
John FiskFrom the Departments of Internal Medicine (R.A.M.) and Community Health Sciences (R.A.M.), University of Manitoba; Department of Community Health Sciences (S.B.P., L.W.S., N.J.), Institute for Public Health (N.J.), Department of Clinical Neurosciences (N.J.), and Hotchkiss Brain Institute (N.J.), University of Calgary; Department of Medicine (Neurology) (H.T.), University of British Columbia, Vancouver; Department of Epidemiology and Biostatistics and Occupational Health (C.W.), McGill University, Montreal; Faculty of Rehabilitation Medicine (S.W.) and School of Public Health (L.W.S.), University of Alberta, Edmonton; Surveillance and Assessment (L.W.S.), Alberta Health, Edmonton; and Departments of Psychiatry and Medicine (J.F.), Dalhousie University, Halifax, Canada.
CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo determine the prevalence of comorbidity in the multiple sclerosis (MS) population at the time of MS diagnosis. We also compared the prevalence of comorbidity in the MS population to that in a matched cohort from the general population.

methodsUsing population-based administrative health data from 4 Canadian provinces, we identified 23,382 incident MS cases and 116,638 age-, sex-, and geographically matched controls. We estimated the prevalence of hypertension, diabetes, hyperlipidemia, heart disease, chronic lung disease, epilepsy, fibromyalgia, inflammatory bowel disease, depression, anxiety, bipolar disorder, and schizophrenia at MS diagnosis using validated case definitions. We compared the populations using rate ratios.

resultsOf the MS cases, 16,803 (71.9%) were female. The most prevalent comorbidity was depression (19.1%). Compared to the matched population, all comorbidities except hyperlipidemia were more common in the MS population. Relative to the matched populations, the prevalence of hypertension was 16% higher for women with MS and 48% higher for men with MS, thus there was a disproportionately higher prevalence of hypertension in men with MS than women. Men with MS also had a disproportionately higher prevalence than women with MS for diabetes, epilepsy, depression, and anxiety.

conclusionsComorbidity is more common than expected in MS, even around the time of diagnosis. The prevalence of psychiatric comorbidity is particularly high and highlights the need for clinical attention to this issue. The observed sex-specific differences in the burden of comorbidity in MS, which differ from those in the matched population, warrant further investigation.

Identifiers

PMID26962066
PMCPMC4826338

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.